• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Jumps 100 Points; US Trade Deficit Widens In September

    11/7/23 12:05:20 PM ET
    $ALTO
    $OPRT
    $SNTI
    $THAR
    Major Chemicals
    Industrials
    Finance: Consumer Services
    Finance
    Get the next $ALTO alert in real time by email

    U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday

    The Dow traded up 0.19% to 34,159.14 while the NASDAQ rose 0.84% to 13,631.99. The S&P 500 also rose, gaining, 0.30% to 4,379.06.

    Check This Out: Top 4 Industrial Stocks That Could Sink Your Portfolio In November

     

    Leading and Lagging Sectors

     

    Information technology shares jumped by 1% on Tuesday.

    In trading on Tuesday, energy shares fell by 2.2%.

     

    Top Headline

     

    The trade deficit in the U.S. increased to $61.5 billion in September versus a revised $58.7 billion gap in the prior month and compared to market estimates of $59.9 billion.

     

    Equities Trading UP

     

    TransMedics Group, Inc. (NASDAQ:TXMD) shares shot up 62% to $65.22 after the company reported better-than-expected third-quarter sales results and issued strong FY23 revenue guidance.

    Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) got a boost, shooting 70% to $0.4974 after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China.

    Tharimmune, Inc. (NASDAQ:THAR) shares were also up, gaining 49% to $0.2350 as the company disclosed the execution of an exclusive worldwide licensing agreement with Avior Inc. d/b/a Avior Bio, LLC to develop, market and commercialize a clinical-stage asset, AV104.

     

    Equities Trading DOWN

     

    Ventyx Biosciences, Inc. (NASDAQ:VTYX) shares dropped 81% to $2.64 after the company announced efficacy results from the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target to support further development of VTX958 in psoriasis.

    Shares of Alto Ingredients, Inc. (NASDAQ:ALTO) were down 58% to $2.04 after the company reported mixed third-quarter financial results.

    Oportun Financial Corporation (NASDAQ:OPRT) was down, falling 45% to $3.22 after reporting a loss for the third quarter.

    Also Check This Out: Jim Cramer Says This Tech Company Reported A 'Dynamite' Quarter: 'I Disliked These Guys For A Long Time, Not Anymore'

     

    Commodities

     

    In commodity news, oil traded down 3% to $78.38 while gold traded down 0.9% at $1,971.00.

    Silver traded down 2.8% to $22.58 on Tuesday while copper fell 1.8% to $3.6530.

     

    Euro zone

     

    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.15%, London’s FTSE 100 fell 0.13% while Spain’s IBEX 35 Index fell 0.18% The German DAX gained 0.05% French CAC 40 fell 0.38%, while Italy’s FTSE MIB Index fell 0.59%.

    Industrial producer prices in the Eurozone declined by 12.4% year-over-year in September versus an 11.5% decline a month ago, while the HCOB construction PMI declined to 42.7 in October from 43.6 in September.

    The S&P Global France construction PMI declined to 41 in October from 43.7 in September, while German construction PMI fell to 38.3 in October, recording the lowest reading since April 2020. Industrial production in Germany fell 1.4% month-over-month for September, while UK’s Halifax House Price Index fell by 3.2% year-over-year in October.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Tuesday, with Japan’s Nikkei 225 falling 1.34%, Hong Kong’s Hang Seng Index declining 1.65% and China’s Shanghai Composite Index falling 0.04%. India’s S&P BSE Sensex, meanwhile, fell around 0.03%.

    China's trade surplus in October 2023 narrowed to $56.53 billion from $82.35 billion in the year-ago-month. Chinese foreign exchange reserves fell to $3.101 trillion in October from the previous month's reading of $3.115 trillion, while foreign exchange reserves in Hong Kong increased to $416 billion in October.

     

    Economics

     

    The Logistics Manager’s Index in the U.S. rose to 56.5 in October versus 52.4 in the prior month.

    The Manheim Used Vehicle Value Index fell 2.3% month-over-month for October.

    The trade deficit in the U.S. increased to $61.5 billion in September versus a revised $58.7 billion gap in the prior month and compared to market estimates of $59.9 billion.

    Now Read This: Insiders Selling Amazon, Costco And 2 Other Stocks

     

    Get the next $ALTO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALTO
    $OPRT
    $SNTI
    $THAR

    CompanyDatePrice TargetRatingAnalyst
    Oportun Financial Corporation
    $OPRT
    1/12/2026$5.50Underweight → Neutral
    Analyst
    Ventyx Biosciences Inc.
    $VTYX
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    Oportun Financial Corporation
    $OPRT
    10/7/2025$6.00Neutral → Underweight
    Analyst
    Oportun Financial Corporation
    $OPRT
    6/12/2025$10.00Overweight
    Stephens
    Senti Biosciences Inc.
    $SNTI
    6/6/2025$5.00Buy
    Laidlaw
    Oportun Financial Corporation
    $OPRT
    3/5/2025$10.00Buy
    BTIG Research
    Oportun Financial Corporation
    $OPRT
    3/15/2024Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $ALTO
    $OPRT
    $SNTI
    $THAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oportun Financial upgraded by Analyst with a new price target

    Analyst upgraded Oportun Financial from Underweight to Neutral and set a new price target of $5.50

    1/12/26 7:47:46 AM ET
    $OPRT
    Finance: Consumer Services
    Finance

    Ventyx Biosciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Ventyx Biosciences from Neutral to Buy and set a new price target of $18.00

    11/5/25 7:25:28 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Senti Bio with a new price target

    H.C. Wainwright initiated coverage of Senti Bio with a rating of Buy and set a new price target of $12.00

    10/14/25 8:53:29 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALTO
    $OPRT
    $SNTI
    $THAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Radkowski Angela Dominy

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    2/11/26 5:20:49 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sommers Jill E.

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    2/11/26 5:18:29 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Wiley William Thomas Jr.

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    2/11/26 5:16:13 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALTO
    $OPRT
    $SNTI
    $THAR
    SEC Filings

    View All

    Oportun Financial Corporation filed SEC Form 8-K: Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Oportun Financial Corp (0001538716) (Filer)

    2/10/26 4:48:21 PM ET
    $OPRT
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by Ventyx Biosciences Inc.

    SCHEDULE 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    2/6/26 4:13:53 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Tharimmune Inc.

    SCHEDULE 13G - Tharimmune, Inc. (0001861657) (Subject)

    2/6/26 4:01:20 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALTO
    $OPRT
    $SNTI
    $THAR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thompson Tommy G bought $14,031 worth of shares (8,400 units at $1.67), increasing direct ownership by 57% to 23,179 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    12/29/25 4:23:31 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Sneed James R bought $3,364 worth of shares (3,176 units at $1.06), increasing direct ownership by 0.74% to 432,397 units (SEC Form 4)

    4 - Alto Ingredients, Inc. (0000778164) (Issuer)

    8/14/25 9:34:09 PM ET
    $ALTO
    Major Chemicals
    Industrials

    Executive Chairman Gravitas Capital Lp bought $500,000 worth of shares (337,838 units at $1.48), increasing direct ownership by 86% to 732,424 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 9:29:23 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALTO
    $OPRT
    $SNTI
    $THAR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

    Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 into R/R AML pivotal study and evaluating indication expansion to include newly diagnosed AML and pediatric AML; Preparing for FDA discussions in the first half of 2026 SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may enable an expedited development and review process SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) --  Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generatio

    2/11/26 8:35:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oportun Strengthens Debt Capital Structure With $485 Million Asset Backed Securitization and Corporate Debt Repayments

    5.32% yield, 45 basis points lower than the prior October 2025 ABS transaction Fourth consecutive sub-6% ABS transaction Repaid $37.5 million of corporate debt during the fourth quarter SAN MATEO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oportun (NASDAQ:OPRT), a mission-driven financial services company, today announced the issuance of $485 million of two-year revolving fixed rate asset-backed notes secured by a pool of unsecured and secured installment loans. The offering included five classes of fixed rate notes: Class A, Class B, Class C, Class D, and Class E. Fitch rated all classes of notes, assigning ratings of AAA, AA-, A-, BBB-, and BB-, respectively. Goldman Sachs & Co. LLC s

    2/9/26 6:11:35 PM ET
    $OPRT
    Finance: Consumer Services
    Finance

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALTO
    $OPRT
    $SNTI
    $THAR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy

    12/29/21 7:23:57 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for IMVEXXY issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug IMVEXXY (SUPPL-2) with active ingredient ESTRADIOL has changed to 'Approval' on 11/16/2021. Application Category: NDA, Application Number: 208564, Application Classification: Labeling

    11/17/21 4:38:32 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-3) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 06/22/2021. Application Category: NDA, Application Number: 210132, Application Classification: Labeling

    6/24/21 5:13:50 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALTO
    $OPRT
    $SNTI
    $THAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Oportun Financial Corporation

    SC 13G - Oportun Financial Corp (0001538716) (Subject)

    11/21/24 4:32:50 PM ET
    $OPRT
    Finance: Consumer Services
    Finance

    SEC Form SC 13D filed by Oportun Financial Corporation

    SC 13D - Oportun Financial Corp (0001538716) (Subject)

    11/20/24 4:02:35 PM ET
    $OPRT
    Finance: Consumer Services
    Finance

    $ALTO
    $OPRT
    $SNTI
    $THAR
    Leadership Updates

    Live Leadership Updates

    View All

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy

    Former Clear Street Group CFO Strengthens Leadership Team Alongside Industry Veterans Mark Wendland and Mark Toomey Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced the appointment of seasoned financial executive Jacob Asbury as Chief Financial Officer, effective immediately. In this role, he will oversee all financial strategy and operations, including capital planning, treasury management, financial reporting, and the continued expansion of Tharimmune's CC treasury infrastructure. Mr. Asbury brings nearly two d

    12/12/25 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALTO
    $OPRT
    $SNTI
    $THAR
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

    Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 into R/R AML pivotal study and evaluating indication expansion to include newly diagnosed AML and pediatric AML; Preparing for FDA discussions in the first half of 2026 SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may enable an expedited development and review process SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) --  Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generatio

    2/11/26 8:35:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, has been selected to deliver an on-stage company presentation at the Healthcare Conference Taipei 2026, co-hosted by J.P. Morgan, UC Berkeley, and the Regent Taipei happening February 10–11, 2026, at the Regent Taipei Hotel. Senti's presentation will be held on Tuesday, February 10, 2026, from 10:30 AM to 10:40 AM local time, in Track 1 at the Reg

    2/3/26 9:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

    Access the segment here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Timothy Lu, MD, PhD, CEO of Senti, discussed its recent news release announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the Company's potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (C

    1/14/26 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care